Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.
Frank D, Patnana PK, Vorwerk J, Mao L, Gopal LM, Jung N, Hennig T, Ruhnke L, Frenz JM, Kuppusamy M, Autry R, Wei L, Sun K, Mohammed Ahmed HM, Künstner A, Busch H, Müller H, Hutter S, Hoermann G, Liu L, Xie X, Al-Matary Y, Nimmagadda SC, Cano FC, Heuser M, Thol F, Göhring G, Steinemann D, Thomale J, Leitner T, Fischer A, Rad R, Röllig C, Altmann H, Kunadt D, Berdel WE, Hüve J, Neumann F, Klingauf J, Calderon V, Opalka B, Dührsen U, Rosenbauer F, Dugas M, Varghese J, Reinhardt HC, von Bubnoff N, Möröy T, Lenz G, Batcha AMN, Giorgi M, Selvam M, Wang E, McWeeney SK, Tyner JW, Stölzel F, Mann M, Jayavelu AK, Khandanpour C. Frank D, et al. Among authors: ruhnke l. Blood. 2023 Dec 21;142(25):2175-2191. doi: 10.1182/blood.2022015752. Blood. 2023. PMID: 37756525 Free PMC article.
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C. Berdel AF, et al. Among authors: ruhnke l. Blood Adv. 2022 Jun 28;6(12):3684-3696. doi: 10.1182/bloodadvances.2021006909. Blood Adv. 2022. PMID: 35468621 Free PMC article. Clinical Trial.
Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation.
Kunadt D, Herold S, Poitz D, Wagenführ L, Kretschmann T, Sockel K, Ruhnke L, Brückner S, Sommer U, Meier F, Röllig C, von Bonin M, Thiede C, Schetelig J, Bornhäuser M, Stölzel F. Kunadt D, et al. Among authors: ruhnke l. Ther Adv Hematol. 2022 Aug 23;13:20406207221115005. doi: 10.1177/20406207221115005. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36050938 Free PMC article.
Next Generation Biobanking: Employing a Robotic System for Automated Mononuclear Cell Isolation.
Fuchs YF, Brunner J, Weigelt M, Schieferdecker A, Morgenstern R, Sturm A, Winter B, Jambor H, Stölzel F, Ruhnke L, von Bonin M, Rücker-Braun E, Heidenreich F, Fuchs A, Bonifacio E, Bornhäuser M, Poitz DM, Altmann H. Fuchs YF, et al. Among authors: ruhnke l. Biopreserv Biobank. 2023 Feb;21(1):106-110. doi: 10.1089/bio.2021.0181. Epub 2022 Oct 13. Biopreserv Biobank. 2023. PMID: 36251308 Free PMC article. No abstract available.
Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
Stölzel F, Fordham SE, Nandana D, Lin WY, Blair H, Elstob C, Bell HL, Mohr B, Ruhnke L, Kunadt D, Dill C, Allsop D, Piddock R, Soura EN, Park C, Fadly M, Rahman T, Alharbi A, Wobus M, Altmann H, Röllig C, Wagenführ L, Jones GL, Menne T, Jackson GH, Marr HJ, Fitzgibbon J, Onel K, Meggendorfer M, Robinson A, Bziuk Z, Bowes E, Heidenreich O, Haferlach T, Villar S, Ariceta B, Diaz RA, Altschuler SJ, Wu LF, Prosper F, Montesinos P, Martinez-Lopez J, Bornhäuser M, Allan JM. Stölzel F, et al. Among authors: ruhnke l. JCI Insight. 2023 Jan 24;8(2):e150368. doi: 10.1172/jci.insight.150368. JCI Insight. 2023. PMID: 36480300 Free PMC article.
Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3- ITD mutations: results of the SAL MIDOKIT trial.
Ruhnke L, Röllig C, Herold S, Sauer T, Brandts CH, Steffen B, Schäfer-Eckart K, Krause SW, Hänel M, Reichle A, Scholl S, Neubauer A, Mikesch JH, Schetelig J, Stölzel F, Kramer M, Haake A, Frimmel J, Krämer A, Schlenk R, Platzbecker U, Serve H, Baldus CD, Müller-Tidow C, Aust D, Bornhäuser M, Ehninger G, Thiede C. Ruhnke L, et al. Haematologica. 2023 Sep 1;108(9):2520-2525. doi: 10.3324/haematol.2022.281636. Haematologica. 2023. PMID: 36779591 Free PMC article. No abstract available.
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Röllig C, Schliemann C, Ruhnke L, Fransecky L, Heydrich BN, Hanoun M, Noppeney R, Schäfer-Eckart K, Wendelin K, Mikesch JH, Middeke JM, Reimann M, Fiebig F, Zukunft S, Wermke M, Serve H, Platzbecker U, Müller-Tidow C, Baldus CD, Bornhäuser M. Röllig C, et al. Among authors: ruhnke l. Br J Haematol. 2024 Jun;204(6):2254-2258. doi: 10.1111/bjh.19436. Epub 2024 Apr 9. Br J Haematol. 2024. PMID: 38593353 Clinical Trial.
61 results